Organon (NYSE: OGN) received FDA acceptance to review a supplemental New Drug Application for its hormone free contraceptive device MIUDELLA. The company entered an exclusive global licensing ...
The Victorian Supreme Court recently dismissed a class action on behalf of more than 1,400 women who received Bayer's Essure contraceptive device. The decision attracted significant publicity, ...
Identify high-growth segments to guide market-entry, expansion, investment and competition strategies while capitalizing on preferred distribution channels.Dublin, Oct. (GLOBE NEWSWIRE) -- "United ...
Please provide your email address to receive an email when new articles are posted on . Ovaprene, a monthly hormone-free contraceptive, blocked motile sperm in an early-phase study. There were no ...
Please provide your email address to receive an email when new articles are posted on . Levonorgestrel-releasing intrauterine system users vs. nonusers had an increased risk for breast cancer. Breast ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Venova Technologies, Inc., a women-led startup developing a novel long-acting, hormone-free and copper-free female birth control device, has been awarded a $2.23M ...
Dublin, Sept. 14, 2026 (GLOBE NEWSWIRE)-- "Australia Reversible Contraceptive Devices Market Outlook to 2033 - Intrauterine Devices (IUDs), Hormonal Implants and Diaphragms" has been added to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results